UY34812A - Método para el tratamiento del cáncer de pulmón de células no pequeñas - Google Patents

Método para el tratamiento del cáncer de pulmón de células no pequeñas

Info

Publication number
UY34812A
UY34812A UY0001034812A UY34812A UY34812A UY 34812 A UY34812 A UY 34812A UY 0001034812 A UY0001034812 A UY 0001034812A UY 34812 A UY34812 A UY 34812A UY 34812 A UY34812 A UY 34812A
Authority
UY
Uruguay
Prior art keywords
treatment
nucleotides
lung cancer
small cells
patient
Prior art date
Application number
UY0001034812A
Other languages
English (en)
Spanish (es)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34812A publication Critical patent/UY34812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UY0001034812A 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas UY34812A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
UY34812A true UY34812A (es) 2013-12-31

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034812A UY34812A (es) 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (https=)
EP (1) EP2849761A1 (https=)
JP (1) JP2015522542A (https=)
KR (1) KR20150024843A (https=)
CN (1) CN104684564A (https=)
AR (1) AR091090A1 (https=)
AU (1) AU2013262589A1 (https=)
BR (1) BR112014028787A2 (https=)
CA (1) CA2874092A1 (https=)
EA (1) EA201492148A1 (https=)
IL (1) IL235459A0 (https=)
IN (1) IN2014DN10390A (https=)
PH (1) PH12014502569A1 (https=)
SG (1) SG11201407649RA (https=)
TW (1) TW201402132A (https=)
UY (1) UY34812A (https=)
WO (1) WO2013173757A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2011143071A2 (en) 2010-05-08 2011-11-17 The Regents Of The University Of California Sem scanner sensing apparatus, system and methodology for early detection of ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
MY194948A (en) * 2016-05-13 2022-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
MX2019004923A (es) 2017-02-03 2019-06-20 Bruin Biometrics Llc Medicion de la susceptibilidad a ulceras del pie diabetico.
KR102402347B1 (ko) 2017-02-03 2022-05-30 브루인 바이오메트릭스, 엘엘씨 부종의 측정
LT3515296T (lt) 2017-02-03 2024-02-12 Bbi Medical Innovations, Llc Audinio gyvybingumo matavimas
AU2018368709C1 (en) 2017-11-16 2025-07-17 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
PT3749181T (pt) 2018-02-09 2024-05-15 Bruin Biometrics Llc Deteção de lesões nos tecidos
CA3115263A1 (en) 2018-10-11 2020-04-16 Bruin Biometrics, Llc Device with disposable element
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
AU2012257487A1 (en) * 2011-05-19 2014-01-16 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
IL235459A0 (en) 2014-12-31
BR112014028787A2 (pt) 2017-06-27
CA2874092A1 (en) 2013-11-21
WO2013173757A1 (en) 2013-11-21
PH12014502569A1 (en) 2015-01-21
AU2013262589A1 (en) 2015-01-22
EP2849761A1 (en) 2015-03-25
WO2013173757A8 (en) 2015-04-30
CN104684564A (zh) 2015-06-03
TW201402132A (zh) 2014-01-16
KR20150024843A (ko) 2015-03-09
SG11201407649RA (en) 2014-12-30
IN2014DN10390A (https=) 2015-08-14
US20130310440A1 (en) 2013-11-21
AR091090A1 (es) 2014-12-30
EA201492148A1 (ru) 2015-04-30
JP2015522542A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
Kim et al. MicroRNA targeting by quercetin in cancer treatment and chemoprotection
Li et al. Targeting long non-coding RNAs in cancers: progress and prospects
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
MX2024005652A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
Schnekenburger et al. Epigenetic modulators from “The Big Blue”: A treasure to fight against cancer
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
MX359548B (es) Agentes de iarn modificados.
AR091004A1 (es) Arn en horquilla corta bifuncional (bi-arnhc) especifico de mutaciones de nucleotidos individuales en k-ras
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
CO7170127A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
EA201590070A1 (ru) ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
IN2014CN03921A (https=)
CY1117000T1 (el) Ενζυματικη αντικαρκινικη θεραπεια
ES2651147T3 (es) Oligonucleótidos para modular la expresión génica y usos de los mismos
AR098819A1 (es) Método y composiciones para el control de insectos plaga en plantas por medio del silenciamiento de genes de la familia de la quitina sintasa y de la vitelogenina así como alternativamente por la expresión del gen de una toxina cry
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR095416A1 (es) Tratamiento con cutirsen que presenta una toxicidad reducida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528